Lexicon Pharmaceuticals, Inc.
$10.7M 20,498 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Astellas Pharma US Inc
Astellas Pharma US Inc reported $10,615,634.48 across General Payments, Research, and Ownership to 147,377 physicians and teaching hospitals across 147,377 transactions.
- $10.6M Top 10% payer
- All-tracks total
- 147,377 Top 10% volume
- Transactions
- 147,377 Top 10% reach
- Recipients
- +$770.1K
- General Payments vs PY2023
Astellas Pharma US Inc reported $10,615,634.48 across all CMS Open Payments tracks (General + Research + Ownership) to 147,377 physicians and teaching hospitals in Program Year 2024 - ranking #165 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $10,615,634.48, averaging $72.03 per recipient.
How Astellas Pharma US Inc's $10.6M all-tracks total breaks down
Astellas Pharma US Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
98/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer astellas-pharma-us-inc Astellas Pharma US Inc
$10.6M · #165/1,925 · 0.1% industry · PY2024
- TOT $10.6M
- RANK #165
- SHARE 0.1%
- TXN 147,377
- RCP 147,377
- CAT 7
- GEN $10.6M
- ΔGEN +$770.1K
- TOP1 8.3%
- PY 2024
Volume peers
Nearest volume peer: Lexicon Pharmaceuticals, Inc. ($10.7M)
Astellas Pharma US Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Astellas Pharma US Inc's CMS-reported General Payments increased by $770.1K (+7.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ASTELLAS PHARMA US INCPY2023: ASTELLAS PHARMA US INCPY2024: Astellas Pharma US Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $9,845,534.13
- PY2024
- $10,615,634.48
What the Data Shows for Astellas Pharma US Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Astellas Pharma US Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Compensation for Services Other Than Consulting" leads the 7-category general-payment breakdown below at $4.0M (37.7% of General Payments, 1,451 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 7 types of general payments, Astellas Pharma US Inc's largest category was "Compensation for Services Other Than Consulting" at $4.0M - 37.7% of General Payments.
Astellas Pharma US Inc reports 7 general-payment categories - the top three are Compensation for Services Other Than Consulting (37.7%), Food and Beverage (31.7%), and Consulting Fee (17.0%). The remaining 4 categories make up 13.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Astellas Pharma US Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $4.0M | 1,451 | 37.7% |
| Food and Beverage | $3.4M | 135,988 | 31.7% |
| Consulting Fee | $1.8M | 243 | 17.0% |
| Education | $672.3K | 7,960 | 6.3% |
| Travel and Lodging | $622.2K | 1,677 | 5.9% |
| Grant | $136.2K | 55 | 1.3% |
| Space Rental or Facility Fees | $7.8K | 3 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,221,821.75 (11.5%) of $10,615,634.48 in this company's General Payments records across 60,722 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Astellas Pharma US Inc
The five named recipients with the highest reported General Payments from this company
- 1
Jennifer Ashton
$876,910.80 across 6 reported transactions
- 2
Peter Kaiser
$105,000.00 across 2 reported transactions
- 3
Seenu Hariprasad
$83,803.01 across 62 reported transactions
- 4
Scott Sellinger
$80,106.26 across 64 reported transactions
- 5
Stephen Freedland
$76,001.68 across 43 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Astellas Pharma US Inc ranks #165 of 1,925 by total payments (top 9% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,711 of 1,838 by HHI (bottom 7% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Elite Orthopedics, Llc : $97.1K total payments, HHI 89
- Biosense Webster, Inc. : $3.2M total payments, HHI 89
- LEO Pharma Inc. : $3.1M total payments, HHI 88
- Medinc of Texas : $86.5K total payments, HHI 87
- Vertical Pharmaceuticals, LLC : $60.9K total payments, HHI 86
- Sight Sciences, Inc. : $1.0M total payments, HHI 85
- Astellas Pharma US Inc (this company) : $10.6M total payments, HHI 85
- Centrix Inc : $17.9K total payments, HHI 84
- Endologix LLC : $725.4K total payments, HHI 84
- Novartis Pharmaceuticals Corporation : $19.7M total payments, HHI 84
- Seapearl East, Inc : $93.9K total payments, HHI 83
- Spinal Elements, Inc. : $50.6K total payments, HHI 83
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Astellas Pharma US Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Astellas Pharma US Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Astellas Pharma US Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Sanofi-Aventis U.s. LLC
$10.7M 42,061 recipients
Compare payment profiles
Ortho-Clinical Diagnostics, Inc.
$10.7M 232 recipients
Compare payment profiles
Treace Medical Concepts, Inc.
$10.5M 10,486 recipients
Compare payment profiles
TG Therapeutics, Inc.
$10.7M 12,185 recipients
Compare payment profiles
Alafair Biosciences, Inc.
$10.8M 704 recipients
Compare payment profiles
Put this to use
Astellas Pharma US Inc ranks #165 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Astellas Pharma US Inc sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Astellas Pharma US Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.